STXBP4

STXBP4 (Synip) is a multidomain scaffold protein that controls vesicular exocytosis, epithelial transcription-factor stability, and Hippo-pathway signaling through distinct domain-mediated protein interactions (PMID:10394363, PMID:19451233, PMID:31782549). In its best-characterized role, STXBP4 selectively binds the t-SNARE syntaxin 4 and inhibits GLUT4 vesicle translocation and glucose transport; insulin stimulation reduces this binding affinity and releases the complex (PMID:10394363). Reconstitution with purified components established that STXBP4 arrests fusion by engaging syntaxin 4 and the syntaxin 4/SNAP-23 t-SNARE complex to block ternary SNARE assembly, an inhibitory activity dominant over Sec1/Munc18 stimulation and selective for cognate GLUT4 exocytic SNAREs (PMID:23665562). The same syntaxin 4-binding activity restrains VAMP2 association and suppresses glucose-stimulated insulin secretion in pancreatic beta cells (PMID:12855681). Insulin-dependent regulation involves Akt2-specific phosphorylation at serine 99 and WW-domain-mediated binding of PIP3, which together govern dissociation from syntaxin 4 and plasma-membrane anchoring of the released protein (PMID:15753124, PMID:22880106); whether S99 phosphorylation is strictly required for GLUT4 translocation is contradicted across studies using S99A versus S99F mutants (PMID:15913552, PMID:17336927). Independent of its SNARE role, STXBP4 stabilizes ΔNp63α in epithelial cells by blocking both RACK1-mediated and APC/C-mediated ubiquitin-dependent degradation, maintaining basal ΔNp63 levels that are lost when STXBP4 is downregulated upon genotoxic stress, and STXBP4 overexpression blocks terminal differentiation and confers oncogenic activity (PMID:19451233, PMID:29735662). STXBP4 also inhibits YAP in the Hippo pathway by assembling an α-catenin-containing complex via WW-domain–PY-motif interactions in an actin-tension-dependent manner (PMID:31782549).

1. 1999 High

   Established STXBP4/Synip as a syntaxin 4-specific binding partner that gates GLUT4 exocytosis and responds to insulin, defining its founding function.

   Evidence Yeast two-hybrid, reciprocal Co-IP, and dominant-negative C-terminal overexpression with GLUT4 translocation assay in adipocytes

   PMID:10394363

   Open questions at the time

   • Did not define the domain or structural basis of syntaxin 4 selectivity
   • Mechanism of insulin-induced affinity reduction unresolved
2. 2003 High

   Extended STXBP4 function beyond adipocytes by showing it suppresses glucose-stimulated insulin secretion in beta cells through syntaxin 4 binding that blocks VAMP2 association.

   Evidence Co-IP and wild-type versus binding-deficient (ΔEF) mutant overexpression with insulin secretion assays in betaHC-9 cells

   PMID:12855681

   Open questions at the time

   • Endogenous loss-of-function not tested
   • Did not address whether beta-cell regulation is also insulin/Akt-dependent
3. 2005 Medium

   Identified Akt2-specific phosphorylation of STXBP4 at S99 as the proposed insulin-regulated switch for syntaxin 4 dissociation and GLUT4 recruitment.

   Evidence In vitro kinase assay with Akt1/2/3 and S99F dominant-negative overexpression in 3T3L1 adipocytes

   PMID:15753124

   Open questions at the time

   • Relies on a dominant-negative phospho-mutant rather than endogenous phospho-detection
   • Directly contradicted by an S99A study the same year
4. 2007 Medium

   Attempted to resolve the S99 controversy, with one study reporting S99A has no effect and another reporting both S99A and S99F block translocation and syntaxin 4 dissociation.

   Evidence Overexpression of S99A (and S99F) mutants in 3T3L1 adipocytes with GLUT4 translocation and syntaxin 4 dissociation assays (two opposing single-lab studies)

   PMID:15913552 PMID:17336927

   Open questions at the time

   • Discrepancy between S99A datasets remains unreconciled
   • Single method, overexpression-based; no endogenous phospho-site validation
5. 2008 Medium

   Provided biochemical confirmation that the STXBP4 C-terminal domain and syntaxin 4 form a direct ~1:1 binary complex, mapping the N-terminal syntaxin 4 region as dispensable.

   Evidence Recombinant co-expression in E. coli, co-purification, and deletion-mapping interaction assays

   PMID:18439908

   Open questions at the time

   • No high-resolution structure of the complex
   • Interaction interface on STXBP4 not defined at residue level
6. 2009 High

   Revealed a SNARE-independent role: STXBP4 stabilizes ΔNp63 by preventing RACK1-mediated proteasomal degradation, linking it to epithelial transcription-factor control and genotoxic stress responses.

   Evidence Co-IP with ΔNp63 and RACK1, STXBP4 siRNA knockdown, and cycloheximide/pulse-chase stability assays in epithelial cells

   PMID:19451233

   Open questions at the time

   • Did not define how genotoxic stress downregulates STXBP4
   • Domain mediating ΔNp63/RACK1 interaction not mapped
7. 2012 Medium

   Defined the WW domain as a PIP3-binding module that anchors dissociated STXBP4 at the plasma membrane and sustains basal GLUT4 levels.

   Evidence Phosphoinositide strip lipid-binding assay, WW-domain deletion mutant, and subcellular fractionation in 3T3L1 adipocytes

   PMID:22880106

   Open questions at the time

   • PIP3 binding affinity and stoichiometry not quantified
   • Relationship between PIP3 anchoring and S99 phosphorylation untested
8. 2013 High

   Established the mechanistic step of fusion inhibition by reconstitution, showing STXBP4 binds the t-SNARE to block ternary complex initiation, dominant over Munc18 stimulation and selective for cognate SNAREs.

   Evidence In vitro reconstituted vesicle fusion with purified components; docking, lipid-mixing, content-mixing, SNARE binding, and Sec1/Munc18 competition assays

   PMID:23665562

   Open questions at the time

   • Insulin/Akt regulation not incorporated into the reconstituted system
   • Structural basis of t-SNARE engagement not resolved
9. 2018 High

   Showed STXBP4 also blocks APC/C-mediated ΔNp63α degradation during M-G1, linking STXBP4 to differentiation control and oncogenic transformation.

   Evidence Co-IP with APC/C components and ΔNp63α, ubiquitination assays, 3D organotypic cultures, soft agar and xenograft assays, APC/C-resistant ΔNp63α mutant

   PMID:29735662

   Open questions at the time

   • How STXBP4 mechanistically shields ΔNp63α from the APC/C is not defined
   • Relationship between RACK1- and APC/C-mediated pathways unclear
10. 2019 High

    Defined a third role as a Hippo-pathway YAP inhibitor that assembles an α-catenin complex via WW-domain–PY-motif binding under actin-tension control.

    Evidence WW-domain binding specificity mapping, Co-IP with α-catenin and Hippo components, YAP reporter assays, and actin perturbation in kidney cancer cells

    PMID:31782549

    Open questions at the time

    • How actin tension is transduced to STXBP4 not defined
    • Relationship to its SNARE and ΔNp63 functions unexplored

• It remains unknown how STXBP4's distinct scaffolding functions across membrane fusion, transcription-factor stability, and Hippo signaling are coordinated within a single protein and whether they operate in the same or distinct cellular contexts.
• No structure of full-length STXBP4 or its complexes
• S99 phosphorylation requirement for GLUT4 translocation remains contradicted
• No unifying model linking WW-domain usage across PIP3, YAP/PY-motif, and ΔNp63 functions